StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Pilocarpin

Pilocarpine

HCID 5910
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
54-71-7
Standard-SMILES
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C
InChIKey
QCHFTSOMWOSFHM-WPRPVWTQSA-N
Summenformel
C11H16N2O2
Durchschnittliche Molmasse
208,26 g/mol
Monoisotopische Masse
208,12117776

Überblick

(+)-pilocarpine is the (+)-enantiomer of pilocarpine. It has a role as an antiglaucoma drug. It is an enantiomer of a (-)-pilocarpine.

Namen und Bezeichner

Bevorzugter Name
Pilocarpine
IUPAC
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
Lokaler Name
Pilocarpin
Englischer Name
PILOCARPINE
Summenformel
C11H16N2O2
Molmasse
208.26

Namen und Synonyme

pilocarpine92-13-7PilokarpinPilocarpolSyncarpineOcusert piloPilocarpinSpersacarpineOcusert pilo-20Ocusert Pilo-40Ocusert P 20ocucarpine
Weitere Namen anzeigen
actone(3S,4R)-3-ethyl-4-((1-Methyl-1H-iMidazol-5-yl)Methyl)dihydrofuran-2(3H)-oneOcusertpilokarpolocusertp20
Pilocarpine muriatePiloviscPilocarpinumDTXSID1021162Spersacarpine hydrochloridePilokarpin monohydrochloride01MI4Q9DI3(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]oxolan-2-one

Datenbank-Bezeichner

CAS
54-71-7、92-13-7
PubChem CID
5910
DTXSID
DTXSID1021162
ChEMBL
CHEMBL550
ChEBI
CHEBI:8207
UNII
01MI4Q9DI3
EC Number
202-128-4
Nikkaji
J9.328I

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,1
Polarare Oberfläche (TPSA)
44,1 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
3
Schwere Atome
15
Formalladung
0
Komplexität
245

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 Einträge

1.1

0.66

Color/Form · 2 Einträge

OIL OR CRYSTALS

NEEDLES

Solubility · 4 Einträge

FREELY SOL IN ETHANOL; INSOL IN DIETHYL ETHER /HCL/

SOL IN WATER, ALC, CHLOROFORM; SPARINGLY SOL IN ETHER, BENZENE; ALMOST INSOL IN PETROLEUM ETHER

SOL IN ETHANOL, DIETHYL ETHER

2.07e+00 g/L

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Antiglaucoma Agents; Miotics; Muscarinic Agonists; Parasympathomimetics;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Ophthalmological preparations > Miotics and antiglaucoma medicines

Boiling Point260 °C @ 5 MM HG (PARTIAL CONVERSION TO ISOPILOCARPINE)
DecompositionON HEATING TO DECOMP, EMITS TOXIC FUMES OF NO(X).

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H300: Fatal if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P271, P284, P301+P316, P304+P340, P316, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Danger

H300+H330 (97.5%): Fatal if swallowed or if inhaled [Danger Acute toxicity, oral; acute toxicity, inhalation]

P260, P264, P270, P271, P284, P301+P316, P304+P340, P316, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Gefahrenhinweise

Regulatory InformationPilocarpine: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)-: Human health tier I assessment
Hazard Classes and Categories · 4 Einträge

Acute Tox. 2 (100%)

Acute toxicity - category 2

Acute toxicity (Oral) - Category 1

Acute Tox. 2 *

Sicherheit und Schutzausrüstung

Storage ConditionsKEEP WELL CLOSED & PROTECTED FROM LIGHT. /HCL/

Toxikologische Informationen

Treatment · 1 Eintrag

Overdosage should be treated with atropine titration (0. 5 mg to 1. 0 mg given subcutaneously or intravenously) and supportive measures to maintain respiration and circulation. Epinephrine (0. 3 mg to 1. 0 mg, subcutaneously or intramuscularly) may also be of value in the presence of severe cardiovascular depression or bronchoconstriction. (L1712)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

S01EB01

S - Sensory organs

N - Nervous system

QN - Nervous system

QS - Sensory organs

S01EB01

Protein BindingPilocarpine does not bind to human or rat plasma proteins over a concentration range of 5 to 25,000 ng/mL. The effect of pilocarpine on plasma protein binding of other drugs has not been evaluated.
Pharmacodynamics · 1 Eintrag

Pilocarpine is a muscarinic agent that mediates diaphoretic, miotic, and central nervous system effects. Pilocarpine stimulates the secretion of various exocrine glands, such as sweat, lacrimal, salivary, and gastrointestinal glands. Following oral administration, pilocarpine increased the mean salivary flow rate by 2- to lO-folds than placebo. Its peak levels were maintained for at least one to two hours. Pilocarpine increases smooth muscle tone, contracts the pupillary and iris sphincter muscles, and induces miosis. Because pilocarpine may affect all five muscarinic receptor subtypes, it is associated with parasympathetic side effects.

Mechanism of Action · 5 Einträge

The muscarinic M3 receptor is expressed in various endocrine and exocrine glands, including the gastric and salivary glands. It is also found in smooth muscle cells in pupillary sphincter and ciliary bodies. The M3 receptor is a G<sub>q</sub>-protein-coupled receptor that activates phospholipase C and upregulates inositol trisphosphate and intracellular calcium. M3 receptor activation has been implicated in smooth muscle contraction and the stimulation of salivary glands. Pilocarpine is an agonist for M1 and M2 receptors, and is a full and partial agonist at the M3 receptor.

...ACT PRIMARILY @ MUSCARINIC RECEPTORS OF AUTONOMIC EFFECTOR CELLS, GANGLIONIC EFFECTS CAN ALSO BE OBSERVED. THIS IS PARTICULARLY TRUE OF PILOCARPINE, ALTHOUGH ITS GANGLIONIC ACTION ALSO INVOLVES STIMULATION OF MUSCARINIC RECEPTORS...

...AFTER TOPICAL INSTILLATION, MIOSIS BEGINS IN 15 TO 30 MIN & LASTS 4 TO 8 HR. REDUCTION OF INTRAOCULAR PRESSURE IS MAXIMAL IN 2 TO 4 HR, WHICH CORRELATES WITH MAX DECR IN OUTFLOW RESISTANCE. EFFECT ON INTRAOCULAR PRESSURE OUTLASTS EFFECT ON OUTFLOW FACILITY...PILOCARPINE...MAY DECR AQUEOUS PRODUCTION.

Zugehörige Reaktionen

10
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1448028
HRID 1448028als Produkt
Reaktionsgleichung von HRID 1461496
HRID 1461496als Produkt
Reaktionsgleichung von HRID 1496356
HRID 1496356als Edukt
Reaktionsgleichung von HRID 1723310
HRID 1723310als Edukt
Reaktionsgleichung von HRID 1723311
HRID 1723311als Edukt
Reaktionsgleichung von HRID 2248544
HRID 2248544als Edukt
Reaktionsgleichung von HRID 2248545
HRID 2248545als Edukt
Reaktionsgleichung von HRID 2254018
HRID 2254018als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Melting Point · 3 Einträge

195-205

34 °C

34 °C

Optical RotationSPECIFIC OPTICAL ROTATION: +106 DEG @ 18 °C/D (2%)
Physical DescriptionSolid
Stability/Shelf Life · 3 Einträge

HYGROSCOPIC. /HCL/

SENSITIVE TO LIGHT.

STABLE IN AIR BUT AFFECTED BY LIGHT. /NITRATE/

Dissociation ConstantsPK1= 7.15; PK2= 12.57 @ 20 °C

Physikochemische Eigenschaften

Schmelzpunkt
34 ° · 34°
Siedepunkt
5 · bp5 260° (partial conversion to isopilocarpine)
Dichte
1.1123 · 1.1123 (rough estimate)
Brechungsindex
1.5 · 1.5000 (estimate)
Löslichkeit
Chloroform (Sparingly, Sonicated), Methanol (Slightly)
pka
6.87 · 6.87(at 30℃)
Aggregatzustand
34 °C · 34°C Liquid
Farbe
Colorless to light yellow
InChI
InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
InChIKey
QCHFTSOMWOSFHM-WPRPVWTQSA-N
SMILES
O1C[C@H](CC2N(C)C=NC=2)[C@H](CC)C1=O
LogP
0.12 · 0.120
CAS Datenbank
92 · 92-13-7(CAS DataBase Reference)
EPA chemische Informationen
2 · 2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S,4R)- (92-13-7)
HepatotoxicityIn clinical trials of pilocarpine, serum enzyme elevations were uncommon and no more frequent than with placebo. Despite, wide scale use, there have been no published reports of acute liver injury attributable to pilocarpine.
Adverse Effects · 1 Eintrag

As the drug acts as a cholinergic agonist, pilocarpine may propagate muscarinic side effects, particularly when used in the oral form. The muscarinic receptors are present in nearly all major organ systems, and muscarinic medications can mediate autonomic function wherever the receptors are present. Due to the receptor's role in mediating the response of the parasympathetic nervous system, stimulation of the receptors will cause "rest and digest" functions throughout the distribution of M1-M5 receptor locations: the neuronal, cardiac, musculoskeletal, pulmonary, digestive, and urinary systems.

Exposure RoutesOral ; eye contact. There was a decrease in the rate of absorption of pilocarpine from SALAGEN Tablets when taken with a high fat meal by 12 healthy male volunteers
Toxicity Summary · 2 Einträge

It is essential to monitor for side effects of excessive stimulation of the muscarinic receptors, as previously due to the systemic effects of the oral preparation. Fortunately, pilocarpine is not among the narrow therapeutic index medications. However, there is no known antidote for treating these side effects, and care should still be taken by the healthcare team to monitor doses and weigh the pros and cons of treatment. If a patient is unable to tolerate the side effects of pilocarpine, they should notify their healthcare team, who may either decrease the dose or discontinue the treatment.

Pilocarpine is a cholinergic parasympathomimetic agent. It increase secretion by the exocrine glands, and produces contraction of the iris sphincter muscle and ciliary muscle (when given topically to the eyes) by mainly stimulating muscarinic receptors.

Natural Pollution Sources · 2 Einträge

PILOCARPINE IS CHIEF ALKALOID OBTAINED FROM LEAFLETS OF SOUTH AMERICAN SHRUBS OF GENUS PILOCARPUS. ...IT WAS LONG KNOWN BY NATIVES THAT CHEWING OF LEAVES OF PILOCARPUS PLANTS CAUSED SALIVATION, 1ST EXPT WERE...PERFORMED IN 1874 BY BRAZILIAN PHYSICIAN NAME COUTINHOU.

FROM PILOCARPUS JABORANDI HOLMES, RUTACEAE: PETIT, POLANOVSKI, BULL SOC CHIM (3) 17, 557, 702 (1897).

Human Toxicity Excerpts · 5 Einträge

LOCAL IRRITATION, ALLERGIC REACTIONS, & SYSTEMIC EFFECTS ARE UNCOMMON. 1 CASE OF MALFUNCTION IN EUSTACHIAN TUBE & DISTURBANCE IN MIDDLE EAR HAS BEEN REPORTED AFTER USE OF 4% SOLN /OF PILOCARPINE/.

HAZINESS OF CORNEAL EPITHELIUM & SUPERFICIAL CORNEAL VASCULARIZATION WITH REDNESS OF CONJUNCTIVA HAVE BEEN OBSERVED...IN 2 PT AFTER LONG-CONTINUED USE OF PILOCARPINE EYEDROPS.

ADVERSE SIDE EFFECTS FROM TOPICAL USE ON EYE ARE FEW, CONSISTING OF SENSATION OF DIMNESS OF VISION...ENFORCED ACCOMMODATION FOR NEAR, CAUSING PSEUDOMYOPIA & IMPROPER FOCUSING...BY PEOPLE BELOW AGE OF PRESBYOPIA. ACHING DISCOMFORT IN EYE FROM CONTRACTION OF CILIARY MUSCLE...@ START OF TREATMENT WITH...EYEDROPS.

SALIVARY, LACRIMAL, GASTRIC, PANCREATIC, & INTESTINAL GLANDS, & MUCOUS CELLS OF RESP TRACT ARE...STIMULATED BY.../PILOCARPINE/. ...AFTER PILOCARPINE, COMPOSITION OF SALIVA TENDS TO APPROACH...ULTRAFILTRATE OF PLASMA. ... GASTRIC GLANDS...SECRETE JUICE...ESP ABUNDANT IN PEPSIN & MUCIN...

For more Human Toxicity Excerpts (Complete) data for PILOCARPINE (12 total), please visit the HSDB record page.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Pilocarpine

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 2 Einträge

ALL PARASYMPATHOMIMETIC DRUGS, IN TOXIC DOSES, STIMULATE ALL SECRETIONS & PRODUCE SEVERE GI COLIC & DIARRHEA & DYSPNEA; IRIS IS MARKEDLY CONSTRICTED; HEART RATE IS 1ST INCR & THEN SLOWED. DEATH MAY BE DUE TO RESP PARALYSIS OR HEART BLOCK. /PARASYMPATHOMIMETIC DRUGS/

...INJECTION OF PILOCARPINE INTO CEREBRAL VENTRICLES OF...RABBIT PRODUCED VARIETY OF AUTONOMIC & SOMATIC MOTOR EFFECTS...PILOCARPINE...BEEN FOUND TO EVOKE CHARACTERISTIC CORTICAL AROUSAL OR ACTIVATION RESPONSE IN CATS FOLLOWING IV INJECTION OF RELATIVELY SMALL DOSES...

Antidote and Emergency TreatmentTREATMENT CONSISTS IN PARENTERAL ADMIN OF ATROPINE, & ADEQUATE MEASURES TO SUPPORT RESP & CIRCULATION & TO COUNTERACT PULMONARY EDEMA.
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
tsca
TSCA listed
ridadr
1544
hs_code
2939800000
risk_code
26/28
hazard_code
T+
safety_code
25-45
hazard_class
6.1(b)
packing_group
III
Giftige Stoffe Daten
92-13-7(Hazardous Substances Data)

...PILOCARPINE /HAS AS/...PRINCIPAL ACTION STIMULATION OF SAME AUTONOMIC EFFECTOR CELLS AS THOSE ACTED UPON BY CHOLINERGIC POSTGANGLIONIC NERVE IMPULSES.

...PILOCARPINE...PRINCIPAL ACTION STIMULATION OF SAME AUTONOMIC EFFECTOR CELLS AS THOSE ACTED UPON BY CHOLINERGIC POSTGANGLIONIC NERVE IMPULSES. IN THIS RESPECT...RESEMBLE CHOLINE ESTERS...

Biological Half-LifeThe elimination half-life was 0.76 and 1.35 hours following administration of a 5mg or lOmg dose 3 times daily, respectively. Following ophthalmic administration in healthy subjects, the half-life was 3.96 hours.
Metabolism/Metabolites · 3 Einträge

There is limited information available about the metabolism of pilocarpine in humans. Inactivation of pilocarpine can occur at neuronal synapses and probably in plasma. Pilocarpine is reported to undergo CYP2A6-mediated 3-hydroxylation to form stereoisomers of 3-hydroxypilocaripine. Pilocaripine also undergoes hydrolysis mediated by paraoxonase 1, a calcium-dependent esterase in plasma and the human liver. Pilocarpic acid is a possible metabolic product of hydrolysis. Pilocarpine metabolites are reported to possess negligible or no pharmacological activity.

Pilocarpine has known human metabolites that include 3-hydroxypilocarpine.

Possibly occurs at the neuronal synapses and in the plasma Half Life: 0.76 hours

FDA Pharmacological Classification · 6 Einträge

01MI4Q9DI3

PILOCARPINE

Mechanisms of Action [MoA] - Cholinergic Agonists

Mechanisms of Action [MoA] - Cholinergic Muscarinic Agonists

Established Pharmacologic Class [EPC] - Cholinergic Receptor Agonist

Pilocarpine is a Cholinergic Receptor Agonist. The mechanism of action of pilocarpine is as a Cholinergic Agonist and Cholinergic Muscarinic Agonist.

MeSH Pharmacological Classification · 2 Einträge

Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here.

Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.

Absorption, Distribution and Excretion · 6 Einträge

Following oral administration of pilocarpine 5mg three times daily in healthy male subjects, peak plasma drug concentrations of 15μg/L were reached in 1.25 hours. At the dose of pilocarpine 10mg three times daily, peak plasma drug concentrations of 41μg/L were reached in 0.85 hours. The rate of absorption is increased when taken with food. Following ophthalmic administration in healthy subjects, the overall median Tmax was 2.2 hours. The mean (SD) Cmax and AUC0-t were 897.2 (287.2) pg/mL and 2699 (741.4) hr x pg/mL, respectively. In patients with presbyopia, the mean Cmax and AUC0-t,ss values were 1.95 ng/mL and 4.14 ng x hr/mL, respectively. The median Tmax was 0.3 hours postdose with a range from 0.2 to 0.5 hours post-dose.

Pilocarpine and its degradation products are eliminated predominantly in the urine.

There is no information available.

There is no information available.

LITTLE DEFINITIVE INFORMATION IS AVAIL ON FATE & ELIMINATION OF PILOCARPINE. IT IS PARTLY DESTROYED IN BODY, BUT LARGER FRACTION IS EXCRETED IN URINE IN COMBINED FORM.

PILOCARPINE PENETRATES EYE WELL; AFTER TOPICAL INSTILLATION...

Cellular LocationsMembrane

Verwendung und Herstellung

Uses · 4 Einträge

MEDICATION (VET)

MEDICATION

Use (kg; approx.) in Germany (2009): >75

For the treatment of radiation-induced dry mouth (xerostomia) and symptoms of dry mouth in patients with Sj&ouml;grens syndrome.

Methods of Manufacturing · 2 Einträge

TOTAL ALKALOIDS ARE EXTRACTED FROM...SUITABLE PILOCARPUS SPECIES, WITH ALC CONTAINING SMALL AMT OF HYDROCHLORIC ACID. SOLVENT DISTD OFF...RESINS ARE ALL DEPOSITED. ...FILTERED...EVAPORATED TO SMALL BULK. AMMONIA IS ADDED IN EXCESS & FREE ALKALOIDS EXTRACTED WITH CHLOROFORM.

PREOBRASHENSKI ET AL, BER 66, 1187 (1933); SAMOKH ALOV, MED PROM SSSR 11, NO 2, 10 (1957)...

Formulations/Preparations · 2 Einträge

ADSORBOCARPINE (BURTON, PARSONS)...ALMOCARPINE (AYERST)...ISOPTO CARPINE (ALCON)...MI-PILO (BARNES-HIND)...MISTURA P (LEDERLE)...PILOCAR (SMP)...PILOCEL (SOFTCON PRODUCTS)...PILOMIOTON (SMP)... /HCL/; PV CARPINE LIQUIFILM (ALLERGAN)...PILOFRIN LIQUIFILM (ALLERGAN)... /NITRATE/

OCUSERT PILO-20, PILO-40 /(ALZA)/

General Manufacturing Information · 5 Einträge

2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S,4R)-: ACTIVE

/PILOCARPINE/ HAS CIS CONFIGURATION; ISOPILOCARPINE IS TRANS: ZAV'VANOL, DOKLADY ADAD NAUK SSSR 82, 257 (1952). ABSOLUTE CONFIGURATION: HILL, BARCZA, TETRAHEDRON 22, 2889 (1966).

INCOMPATIBILITIES: SILVER NITRATE, MERCURY BICHLORIDE, IODIDES, GOLD SALTS, TANNIN, CALOMEL, POTASSIUM PERMANGANATE, ALKALIES.

/OCUSERT/...IS ELLIPTICALLY SHAPED UNIT...OF PILOCARPINE-CONTAINING RESERVOIR SURROUNDED BY PERMEABLE MEMBRANE. FOLLOWING PLACEMENT BY PT, DIFFERENT FORMS OF UNIT ARE DESIGNED TO RELEASE PILOCARPINE @ RATE OF EITHER 20 OR 40 UG/HR FOR 1 WK. INTRAOCULAR PRESSURE IS REDUCED CONTINUOUSLY...WITH...LESS TOTAL DRUG...

PILOCARPINE HYDROCHLORIDE & PILOCARPINE NITRATE ARE OFFICIAL IN USP BOTH AS SALTS & AS OPHTHALMIC SOLN. AVG ORAL OR HYPODERMIC DOSE OF PILOCARPINE, NOW RARELY USED, IS 5 TO 10 MG. DEVICE FOR ACHIEVING SUSTAINED RELEASE OF PILOCARPINE INTO CUL-DE-SAC OF EYE IS ALSO AVAIL (OCUSERT).

Anwendungen · 3 Einträge

BeschreibungPilocarpine acts by stimulating muscarinic receptors, therefore making it similar in action to acetylcholine when systematically introduced. This compound differs from acetylcholine in that it does not react with any nicotinic receptors, but by stimulating the CNS. Its effects are blocked by atropine. It has found therapeutic use in ophthalmology as a myotic agent.

HistoryIt has a history of hundreds of years since pilocarpine was used to treat glaucoma .In 1933, the chemical synthesis of pilocarpine was firstly reported. However, pilocarpine couldn’t be used for treatments, because its synthetic route is so long and focuses on isopilocarpine, of which the pharmacological activities are 1/20– 1/50 of pilocarpine. In 1972, DeGraw successfully synthesized the cis-homopilopic acid employing catalytic hydrogenation of precious metals and obtained pilocarpine as the main part product. Therefore, the study on the production of pilocarpine by chemical synthesis has made new progress and has been artificially synthesized .

VerwendenPilocarpine occurs in the leaves of variousspecies of pilocarpus. It is used as an antidotefor atropine poisoning and in ophthalmologyto produce contraction of the pupil.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

HydrogenchloridDiisobutylaluminiumhydridNatriumhydridPalladiumdihydroxidN,N-Dimethylpyridin-4-amin3-Acetyl-2(5H)-furanone(4-ETHYL-5-OXO-TETRAHYDRO-FURAN-3-YL)-ACETALDEHYDEButanedioic acid, 2-bromo-3-ethyl-, 4-methyl ester, [S-(R*,S*)]- (9CI)

Ergänzende Hinweise

DefinitionChEBI: The (+)-enantiomer of pilocarpine.